human dopamine d1 receptor

UCM-1306 is a potent and orally active allosteric modulator (PAM) of the human dopamine D1 receptor. It increases the maximal effect of endogenous dopamine (DA) in both human and mouse D1 receptors. UCM-1306 could improve motor symptoms and address key comorbid cognitive impairment associated with long-term Parkinson's disease (PD).

GR 103691, a potent and selective dopamine D3 receptor antagonist (Ki: 0.4 nM), exhibits more than 100-fold selectivity for human dopamine D3 receptors over human D4 and D1 sites.

LY3154207 is a subtype selective, potent, and orally available human dopamine D1 receptor positive allosteric modulator (PAM) with minimal allosteric agonist activity (EC50=3 nM).

PF2562 is a dopamine D1 ligand. It is used as a dopamine D1 agonist or partial agonist. PF2562 binds to human D1 receptor (Ki: 113 nM). PF2562 shows activity against human D1 cAMP (EC50: 568 nM in HTRF assay).

A-381393 is a selective and brain penetrate dopamine D4 receptor antagonist (Kis: 1.9 1.5 1.6 nM for human dopamine D4.2 D4.4 D4.7 receptor).

DETQ, a selective, allosteric, and orally active potentiator of the dopamine D1 receptor (Dopamine Receptor), enhances cAMP production in HEK293 cells expressing the human D1 receptor, achieving an EC50 of 5.8 nM and a K b of 26 nM. It demonstrates approximately 30-fold reduced potency at rat and mouse D1 receptors and shows no activity at the human D5 receptor [1].